Home Overview Press Room Blog Publications For Students about us
Search

About Assisted Reproduction


Most assisted reproductive technologies (ART) are used to treat infertility. Others are used when there are no fertility problems. Embryo screening or pre-implantation genetic diagnosis, for example, is used in order to prevent the births of children with specific genetic characteristics.

In vitro fertilization (IVF) refers to assisted reproduction procedures in which sperm and eggs are joined outside a woman's body. Women undergoing IVF are given hormonal drugs to promote the development of multiple eggs, which are retrieved with a minor surgical procedure. The eggs are mixed with sperm; one or more of those that fertilize are then transferred to the woman's uterus.

IVF has been in use since 1978 and has resulted in almost four million births worldwide. A number of IVF-related techniques have been introduced since then. Some of these, such as pre-implantation genetic diagnosis and commercial gestational surrogacy, raise significant ethical and policy concerns. In the United States alone, the assisted reproduction business is estimated to create over $3 billion in revenues a year.

Research on the risks associated with ART is notoriously inadequate. There have been few follow-up studies either on women who have used ARTs or their children. The United States is also known for having few laws governing assisted reproduction and little oversight of ART facilities.



Breaking Taboo, Swedish Scientist Seeks To Edit DNA Of Healthy Human Embryos[citing CGS' Marcy Darnovsky]by Rob SteinNPRSeptember 22nd, 2016CRISPR gene editing human embryos is a step toward attempts at producing genetically modified humans. It's not a technology to be taken lightly.
Will Genetic Engineering Really Change Everything Forever? [Video Review]by Elliot HosmanSeptember 8th, 2016The hype surrounding CRISPR gene editing and a future of designer babies is on playback with a popular new video. Is its optimism justified? And who decides what’s inevitable?
Victory: Eggs-for-Research Bill Dies in California Legislatureby Emily Galpern, Biopolitical Times guest contributorSeptember 8th, 2016A bill that would have expanded the commercial markets for human eggs, putting women’s health at risk, never made it to the Governor’s desk.
Remembering Ruth Hubbardby Marcy DarnovskySeptember 8th, 2016Ruth Hubbard — biologist, feminist scholar, social justice advocate, and critic of what she termed “the gene myth” — has died.
5 Reasons Why We Need People with Disabilities in the CRISPR Debatesby Emily Beitiks, Biopolitical Times guest contributorSeptember 8th, 2016“Why do I have to keep justifying my existence?” How gene editing policy discussions reproduce ableist assumptions and generate advocacy fatigue.
Two Women Pregnant after Having Ovarian Mitochondria Injected into EggsThe Japan TimesAugust 30th, 2016Some experts are calling for a careful response to the new procedure, as its safety and effects have not yet been scientifically verified.
Sperm Donor at Heart of Canadian Lawsuits Admits He Lied to Company Xytex, Police Sayby Diana MehtaThe Canadian PressAugust 30th, 2016Amidst pending lawsuits, Sperm Donor 9623 has turned himself in to the police for "falsifying paperwork."
Surrogates are Workers, Not Wombsby Amrita PandeThe HinduAugust 29th, 2016Assumptions about women and reproduction derail effective worker protections in surrogacy regulation, as seen in India's draft legislation.
Why India’s New Surrogacy Bill Is Bad For Womenby Sharmila RudrappaThe Huffington PostAugust 26th, 2016In an attempt to regulate surrogacy, the bill has further deregulated the industry and opened the possibilities for deeper harms to working class women.
Surrogacy Still Big Business in Shanghai Despite National Banby Alice YanSouth China Morning PostAugust 25th, 2016Since China's one-child policy relaxed two years ago, the surrogacy industry has been expanding despite recent police raids.
Displaying 1-10 of 1497  
Next >> 
Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1122 University Ave, Suite 100, Berkeley, CA 94702 • • (p) 1.510.665.7760 • (F) 1.510.665.8760